Familial hypercholesterolemia: Executive summary of the Japan atherosclerosis society(JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 1, 2014, Pages 6-10

  Teramoto, Tamio ^a   Sasaki, Jun ^a   Ishibashi, Shun ^a   Birou, Sadatoshi ^a   Daida, Hiroyuki ^a   Dohi, Seitaro ^a   Egusa, Genshi ^a   Hiro, Takafumi ^a   Hirobe, Kazuhiko ^a   Iida, Mami ^a   Kihara, Shinji ^a   Kinoshita, Makoto ^a   Maruyama, Chizuko ^a   Ohta, Takao ^a,a   Okamura, Tomonori ^a   Yamashita, Shizuya ^a   Yokode, Masayuki ^a   Yokote, Koutaro ^a   Harada Shiba, Mariko ^a   Arai, Hidenori ^a   Bujo, Hideaki ^a   Nohara, Atsushi ^a   Oikawa, Shinichi ^a   Okada, Tomoo ^a   Wakatsuki, Akihiko ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLESTILAN; COLESTYRAMINE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; PROBUCOL;

ACHILLES TENDON; APHERESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC ANALYSIS; HUMAN; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; NOTE; RADIOGRAPHY; RISK FACTOR; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; JAPAN; PRACTICE GUIDELINE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; JAPAN; RISK FACTORS;

EID: 84892966997     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.20040     Document Type: Note

References (11)

1. Mabuchi H, Koizumi J, Shimizu M, Takeda R: Development of coronary heart disease in familial hypercholesterolemia. Circulation, 1989; 79: 225-232
2. Harada-Shiba M, Arai H, Okamura T, Yokote K, Oikawa S, Nohara A, Okada T, Ohta T, Bujo H, Watanabe M, Wakatsuki A, Yamashita S: Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2012; 19: 1019-1026
3. Report of investigation and research group on primary hyperlipidemia in 2011
4. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K: Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version-Treatment A) Lifestyle Modification. J Atheroscler Thromb, in press
5. Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, Yamashita T, Miyamoto Y, Yamamoto A, Tomoike H, Yokoyama S: Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2010; 17: 667-674
6. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Longterm probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2008; 15: 292-303
7. Okada T, Murata M, Yamauchi K, Harada K: New criteria of normal serum lipid levels in Japanese children: the nationwide study. Pediatr Int, 2002; 44: 596-601
8. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J; American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research: Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation, 2006; 114: 2710-2738
9. Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R; NICE Guideline Development Group; NICE Guideline Development Group: Identification and management of familial hypercholesterolaemia: what does it mean to primary care? Br J Gen Pract, 2009; 59: 773-776
10. Thorogood M, Seed M, De Mott K: Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG, 2009; 116: 478-479
11. Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S: Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 1043-1060